{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:50:50Z","timestamp":1788047450411,"version":"build-2784847793"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T00:00:00Z","timestamp":1320969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T00:00:00Z","timestamp":1320969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1038\/leu.2011.323","type":"journal-article","created":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T09:55:36Z","timestamp":1321005336000},"page":"1189-1194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results"],"prefix":"10.1038","volume":"26","author":[{"given":"P D","family":"le Coutre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F J","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J F","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G J","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Blakesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Shou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N J","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H M","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,11]]},"reference":[{"key":"BFleu2011323_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O\u2019Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164\u2013172.","journal-title":"N Engl J Med"},{"key":"BFleu2011323_CR2","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330\u20131340.","journal-title":"N Engl J Med"},{"key":"BFleu2011323_CR3","first-page":"49","volume":"25","author":"JE Sokal","year":"1988","unstructured":"Sokal JE, Baccarani M, Russo D, Tura S . Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988; 25: 49\u201361.","journal-title":"Semin Hematol"},{"key":"BFleu2011323_CR4","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","volume":"61","author":"HM Kantarjian","year":"1988","unstructured":"Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441\u20131446.","journal-title":"Cancer"},{"key":"BFleu2011323_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3324\/haematol.13529","volume":"94","author":"F Palandri","year":"2009","unstructured":"Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S et al. The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600\u2009mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009; 94: 205\u2013212.","journal-title":"Haematologica"},{"key":"BFleu2011323_CR6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/cncr.21756","volume":"106","author":"JE Cortes","year":"2006","unstructured":"Cortes JE, Talpaz M, O\u2019Brien S, Faderl S, Garcia-Manero G, Ferrajoli A et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 2006; 106: 1306\u20131315.","journal-title":"Cancer"},{"key":"BFleu2011323_CR7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876\u2013880.","journal-title":"Science"},{"key":"BFleu2011323_CR8","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on chronic myeloid leukemia. Clin Cancer Res 2006; 12: 7374\u20137379.","journal-title":"Clin Cancer Res"},{"key":"BFleu2011323_CR9","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","volume":"20","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O\u2019Brien S et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 1767\u20131773.","journal-title":"Leukemia"},{"key":"BFleu2011323_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Br\u00fbggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFleu2011323_CR11","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","volume":"11","author":"M Golemovic","year":"2005","unstructured":"Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005; 11: 4941\u20134947.","journal-title":"Clin Cancer Res"},{"key":"BFleu2011323_CR12","doi-asserted-by":"publisher","first-page":"6977","DOI":"10.1016\/j.bmc.2010.08.026","volume":"18","author":"PW Manley","year":"2010","unstructured":"Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 2010; 18: 6977\u20136986.","journal-title":"Bioorg Med Chem"},{"key":"BFleu2011323_CR13","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500\u20134505.","journal-title":"Cancer Res"},{"key":"BFleu2011323_CR14","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD . AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94: 1765\u20131769.","journal-title":"Br J Cancer"},{"key":"BFleu2011323_CR15","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542\u20132551.","journal-title":"N Engl J Med"},{"key":"BFleu2011323_CR16","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P le Coutre","year":"2008","unstructured":"le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111: 1834\u20131839.","journal-title":"Blood"},{"key":"BFleu2011323_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28\u201337.","journal-title":"Blood"},{"key":"BFleu2011323_CR18","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","volume":"20","author":"S Branford","year":"2006","unstructured":"Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006; 20: 1925\u20131930.","journal-title":"Leukemia"},{"key":"BFleu2011323_CR19","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"MC Muller","year":"2009","unstructured":"Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957\u20131963.","journal-title":"Leukemia"},{"key":"BFleu2011323_CR20","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330\u20133338.","journal-title":"Blood"},{"key":"BFleu2011323_CR21","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"T Hughes","year":"2009","unstructured":"Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Muller MC et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009; 27: 4204\u20134210.","journal-title":"J Clin Oncol"},{"key":"BFleu2011323_CR22","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928\u20131937.","journal-title":"Blood"},{"key":"BFleu2011323_CR23","doi-asserted-by":"publisher","first-page":"11a","DOI":"10.1182\/blood-2003-09-3363","volume":"104","author":"RT Silver","year":"2004","unstructured":"Silver RT, Talpaz M, Sawyers CL, Druker BJ, Hochhaus A, Schiffer CA et al. Four years of follow-up of 1027\u2009patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 2004; 104: 11a (abstract 23).","journal-title":"Blood"},{"key":"BFleu2011323_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2009.006999","volume":"94","author":"RT Silver","year":"2009","unstructured":"Silver RT, Cortes J, Waltzman R, Mone M, Kantarjian H . Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica 2009; 94: 743\u2013744.","journal-title":"Haematologica"},{"key":"BFleu2011323_CR25","doi-asserted-by":"publisher","first-page":"18292","DOI":"10.1074\/jbc.M801337200","volume":"283","author":"N Vajpai","year":"2008","unstructured":"Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, Grzesiek S et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib. J Biol Chem 2008; 283: 18292\u201318302.","journal-title":"J Biol Chem"},{"key":"BFleu2011323_CR26","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540\u20133546.","journal-title":"Blood"},{"key":"BFleu2011323_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/leu.2008.160","volume":"23","author":"A Shimoni","year":"2009","unstructured":"Shimoni A, Leiba M, Schleuning M, Martineau G, Renaud M, Koren-Michowitz M et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemia. Leukemia 2009; 23: 190\u2013194.","journal-title":"Leukemia"},{"key":"BFleu2011323_CR28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood.V112.11.1106.1106","volume":"112","author":"HM Kantarjian","year":"2008","unstructured":"Kantarjian HM, Kim D, Dorlhiac-Llacer P, Pasquini R, Khoroshko N, DiPersio JF et al. Dasatinib 140\u2009mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70\u2009mg twice daily (BID) in patients with accelerated phase chronic myeloid leukemia (CML-AP): 2-year follow-up data from CA180-035. Blood 2008; 112: 1106\u20131107.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2011323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011323","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2011323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:46:36Z","timestamp":1648737996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2011323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["BFleu2011323"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.323","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,11]]},"assertion":[{"value":"24 January 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PDleC received research funding and honoraria from Bristol\u2013Myers Squibb and Novartis, and participated in speakers\u2019 bureaus for Bristol\u2013Myers Squibb and Novartis. FJG acted as a consultant for and received research funding and honoraria from Novartis. AH acted as a consultant for Ariad, Bristol\u2013Myers Squibb and Novartis, received research funding from Bristol\u2013Myers Squibb, Novartis and Pfizer, and received honoraria from and participated on advisory committees for Bristol\u2013Meyers Squibb and Novartis. JFA received research funding from Novartis, received honoraria from Bristol\u2013Myers Squibb, Chemgenex and Novartis, and participated on advisory committees for Ariad, Bristol\u2013Myers Squibb, Chemgenex and Novartis. GJO acted as a consultant for and received research funding from Novartis, and has received honoraria and participated on advisory committees for Bristol\u2013Myers Squibb and Novartis. RB and YS are Novartis employees. NJG is an employee and shareholder of Novartis. MB has received research funding from Novartis and acted as a consultant for, received honoraria from and participated in speakers\u2019 bureaus for Bristol\u2013Myers Squibb and Novartis. JC acted as a consultant for Bristol\u2013Myers Squibb, Chemgenex and Pfizer, and received research funding from Ariad, Bristol\u2013Myers Squibb, Chemgenex, Novartis and Pfizer. HMK acted as a consultant for Novartis, and received research funding from Bristol\u2013Myers Squibb, Novartis and Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}